Stockhouse.com uses cookies on this site. By continuing to use our service, you agree to our use of cookies. Cookies are used to offer you a better browsing experience and to analyze our traffic. We also use them to share usage information with our partners. See full details.
I Agree
×
Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Privacy Policy | Disclaimer

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Privacy Policy | Disclaimer
Please Try Again {{ error }}

Send my password

Return to Login
SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Breaking & Recent News ARIAD Pharmaceuticals ARIA

Healthcare Biotechnology
"ARIAD Pharmaceuticals Inc is an oncology company. The Company is engaged in transforming the lives of cancer patients with breakthrough medicines. It commercializes & develops products and product candidates including Iclusig, Brigatinib, and AP32788."

Recent & Breaking News (NDAQ:ARIA)

ARIAD Announces Longer-Term Safety and Efficacy Data of Ponatinib from PACE and Phase 1 Clinical Trials

Business Wire June 2, 2014

ARIAD Announces Initial Data from Phase 2 Trial of Ponatinib in Patients with Gastrointestinal Stromal Tumors

Business Wire June 1, 2014

ARIAD Announces Preliminary Safety and Efficacy Data of Ponatinib in Patients with Newly Diagnosed CML from Discontinued Phase 3 EPIC Trial

Business Wire May 31, 2014

ARIAD Presents Updated Phase 1/2 Data on AP26113 in Patients with ALK+ Non-Small Cell Lung Cancer

Business Wire May 31, 2014

ARIAD to Present at Upcoming Investor Conferences

Business Wire May 28, 2014

ARIAD Announces Data Presentations and Webcast of Investor Briefing at the 2014 ASCO Annual Meeting

Business Wire May 14, 2014

ARIAD to Present at UBS Global Healthcare Conference

Business Wire May 13, 2014

ARIAD Reports First Quarter 2014 Financial Results and Development Progress

Business Wire May 7, 2014

ARIAD to Webcast Conference Call on First Quarter 2014 Financial Results

Business Wire April 16, 2014

Ariad Pharmaceuticals (ARIA) Pulls Back on Signs its Overbought

Equities.com April 2, 2014

DJIA, S&P 500 Gain on ADP Jobs Report, Increased Factory Orders

Equities.com April 2, 2014

ARIAD Announces Appointment of Hugh Cole, Senior Pharmaceutical-Industry Executive, as Chief Business Officer

Business Wire April 2, 2014

Ariad Pharmaceuticals (ARIA) Jumps on More Buyout Rumors

Equities.com March 28, 2014

Stocks Hold Out Against Late Biotech Sell-Off as Wall Street Nudges Higher

Equities.com March 28, 2014

ARIAD Announces Initiation of Pivotal Phase 2 ALTA Trial of AP26113 in Patients with Non-Small Cell Lung Cancer

Business Wire March 24, 2014

Workday Upgraded to $150 a Share; Ariad Pharmaceuticals Q4 Loss Widens

Accesswire February 28, 2014

ARIAD Reports 2013 Financial Results and Outlines Key Objectives for 2014

Business Wire February 25, 2014

ARIAD to Present at the Cowen and Company 34th Annual Health Care Conference

Business Wire February 24, 2014

ARIAD Expands Its Board of Directors with Appointment of Alexander J. Denner, Ph.D. of Sarissa Capital Management

Business Wire February 21, 2014

Facebook to Buy Messaging App WhatsApp; Garmin Ltd. Hits New 1-year High on Earnings

Accesswire February 20, 2014